Table 3.

Clinical parameters from cohort as compared to clinical trial

	UNC, median (range)	Kruse-Jarres et al,14 median
Total dose/24 h, U/kg	200 (100-400)	741
Cumulative dose, U/kg	512.5 (150-8625)	2057
Initial dose, U/kg	100 (50-200)	200
First-dose FVIII recovery, %	99.5 (<1-318)	216
Peak FVIII activity/24-h period, %	136 (<1-391)	308
Dosing interval, h	8 (4-24)	10.2

Comparison of select clinical and laboratory parameters between our cohort and the phase 2/3 trial that led to FDA approval of rpFVIII for use in AHA.